Other languages Bristol-Myers Squibb Company Xetra

Equities

BRM

US1101221083

Market Closed - Xetra Other stock markets 11:35:32 2024-06-26 EDT			5-day change	1st Jan Change
39.85 ^EUR	+0.99%		+4.17%	-14.12%

06-26	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
06-26	Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26
Bristol Myers : approbation accélérée en cancer colorectal	06-24
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-21
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	06-21
US FDA approves Bristol Myers' colorectal cancer therapy	06-21
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	06-21
Bristol Myers : demande validée pour Opdivo sous-cutané	06-21
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	06-21
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	06-19
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	06-18
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	06-18
Bristol Myers : dividendes décidés par le conseil	06-18
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	06-18
Bristol Myers : approbation de la FDA pour un traitement	06-14
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	06-13
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	06-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm